- Moderna has revised its full-year revenue forecast to a range between $1.5 billion and $2.2 billion, down from a previous high of $2.5 billion. The expectation is $2.07 billion.
- Capital expenditures are expected to be around $300 million, reduced from a prior forecast of about $400 million, with an estimate of $398.8 million.
- The company reported a second-quarter loss per share of $2.13, which is an improvement from a loss per share of $3.33 year-on-year.
- Revenue for the second quarter was $142 million, a decrease of 41% year-on-year, but exceeded the estimate of $108.5 million.
- Covid-19 vaccine revenue for the second quarter was $114 million.
- Total operating expenses fell by 35% year-on-year to $1.05 billion, against an estimate of $1.36 billion.
- Cost of goods sold increased by 3.5% year-on-year to $119 million, compared to an estimate of $78.1 million.
- Research and Development expenses were $700 million, below the estimate of $1.01 billion.
- Sales, General, and Administrative expenses fell by 14% year-on-year to $230 million, under the estimated $252.7 million.
- Operating loss was $907 million, a 33% reduction year-on-year, against an estimated loss of $1.22 billion.
- Cash and cash equivalents were $1.28 billion, lower than the estimated $1.58 billion.
- The reduction in the high-end range of the full-year revenue guidance is mainly due to a timing shift in deliveries of contracted revenue for the UK into the first quarter of 2026.
- For the second half of the year, Moderna anticipates a revenue split of 40% to 50% in the third quarter, with the remaining balance expected in the fourth quarter.
“`
Moderna on Smartkarma
Analysts at Baptista Research have provided insightful coverage of Moderna on Smartkarma, a platform where independent analysts share their research. One of the reports, titled “Moderna Inc.: Will Its Oncology Innovations & Pipeline Expansion Become The MUCH NEEDED Breakthrough After The Covid Vaccine?”, examines Moderna’s recent earnings. The report highlights the first-quarter 2025 revenues of $0.1 billion and a net loss of $1 billion. Despite the loss aligning with company expectations and reflecting the seasonal nature of its respiratory vaccine business, the analysis suggests potential breakthroughs in oncology innovations post the Covid vaccine.
In another report by Baptista Research, titled “Moderna Inc.: Is Its mRNA Platform Fueling A Multi-Billion-Dollar Pipeline Beyond COVID?”, the analysts delve into Moderna’s financial results for 2024. The report reveals that Moderna recorded a total revenue of $3.2 billion for the year, marking a 53% decrease from 2023 due to declining product sales. Additionally, the net loss for 2024 improved slightly to $3.6 billion from $4.7 billion in 2023. With a bullish sentiment, the analysis explores the potential of Moderna’s mRNA platform in driving a multi-billion-dollar pipeline beyond the Covid era, presenting both opportunities and challenges for the company.
A look at Moderna Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Moderna, Inc. operates as a biotechnology company with a strong focus on the discovery and development of messenger RNA therapeutics and vaccines. The company has received promising Smartkarma Smart Scores across various factors. With a high Value score of 4, Moderna is considered to be positioned well in terms of its financial value relative to its industry peers. Additionally, the company has demonstrated positive Momentum with a score of 4, indicating a strong uptrend in its stock performance.
However, there are areas where Moderna could potentially improve. Despite a lower Dividend score of 1, suggesting a lack of dividend payouts to shareholders, the company has room for growth with a score of 2. Furthermore, Moderna has shown Resilience with a score of 3, highlighting its ability to adapt and withstand market volatility. In summary, Moderna’s outlook remains positive with strengths in value and momentum, while areas such as growth and resilience present opportunities for further development.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
